Mental Health Clinics in Clinton, IL Accepting Medicare
3 Mental Health Clinics found. Showing 1 - 3
 Heritage Behavioral Health Center Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 40 Clinton Plz, Hwy 54, Clinton, IL 61727 Phone: 217-362-6262 Fax: 217-362-6290 |
Lifeway Behavioral Health Services Inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 200 E Main St, Clinton, IL 61727 Phone: 217-935-3900 |
Heritage Behavioral Health Center Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 140 Sunrise Ct, Clinton, IL 61727 Phone: 217-362-6262 Fax: 217-362-6290 |
News Archive
11 "snips" associated with type 2 diabetes
Mathematicians at Michigan Technological University have developed powerful new tools for winnowing out the genes behind some of humanity's most intractable diseases.
Omeros doses first patient in second Phase 2 clinical trial of OMS824
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
Office-based duplex guided hemodialysis access angioplasty safe: Study
Duplex guided dialysis access angioplasty can be performed safely and effectively in the office setting according to a new study presented today at the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery®. According to researchers, ultrasound offers the advantage of treating the patient without ionizing radiation and sedation or iodinated contrast.
Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.
› Verified 6 days ago